04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
21:15 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers A panel of 40 DNA damage repair signatures in tumors could help predict survival in eight types of cancer. The 40 signatures, including homologous recombination and loss-of-heterozygosity signatures, are calculated...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
02:41 , Oct 29, 2015 |  BC Extra  |  Clinical News

AZ's olaparib leads to responses in CRPC

Data published Wednesday in the New England Journal of Medicine showed olaparib ( AZD2281 ) from AstraZeneca plc (LSE:AZN; NYSE:AZN) led to a response in 33% of patients in the Phase II TOPARP-A study to...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Quest Diagnostics sales and marketing update

Quest launched BRCAvantage Plus in the U.S. to screen for mutations in breast cancer 1 early onset (BRCA1) , BRCA2 , tumor protein p53 (TP53) , phosphatase and tensin homolog deleted on chromosome ten (...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Pathway Genomics sales and marketing update

Pathway launched its BreastTrue High Risk Panel. The next-generation sequencing test with deletion/duplication analysis detects mutations in seven high-risk breast cancer susceptibility genes, including the breast cancer 1 early onset (BRCA1) , BRCA2 and partner...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Invitae sales and marketing update

Invitae launched PALB2 testing worldwide to diagnose cancer. The test includes full sequencing and deletion/duplication analysis of the partner and localizer of BRCA2 (PALB2) gene for $1,500 in the U.S. and has a turnaround time...
07:00 , Jun 6, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model for partner and localizer of Brca2 (Palb2)-deficient breast cancer A mouse model for Palb2-deficient breast cancer could be useful for evaluating new therapies....
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Myriad Genetics sales and marketing update

Myriad Genetics launched Panexia in the U.S. to assess the risk of developing pancreatic cancer later in life. The molecular diagnostic analyzes the partner and localizer of BRCA2 (PALB2) and breast cancer 2 early onset...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Company News

Myriad Genetics, Johns Hopkins University deal

Myriad received an exclusive, worldwide license to the university's patents covering mutations in the partner and localizer of BRCA2 (PALB2) . PALB has been associated with an increased risk of pancreatic cancer. Myriad will use...